Oral anticoagulants in the management of venous thromboembolism

Nature Reviews Cardiology

Volumn 10, Issue 7, 2013, Pages 397-409

  Makaryus, John N ^a   Halperin, Jonathan L ^b   Lau, Joe F ^a  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; DABIGATRAN; EDOXABAN; ENOXAPARIN; PLACEBO; RIVAROXABAN; WARFARIN;

BLEEDING; BLOOD CLOTTING; DRUG ADMINISTRATION ROUTE; HUMAN; PRIORITY JOURNAL; REVIEW; THROMBOSIS; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD COAGULATION; DRUG THERAPY, COMBINATION; HUMANS; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84881110926     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2013.73     Document Type: Review

References (90)

1. Steffel, J., Luscher, T. F. & Tanner, F. C. Tissue factor in cardiovascular diseases: Molecular mechanisms and clinical implications. Circulation 113, 722-731 (2006).
2. Hart, R. G., Pearce, L. A. & Aguilar, M. I. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 146, 857-867 (2007).
3. Guyatt, G. H. et al. Executive summary: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141 (Suppl. 2), 7S-47S (2012).
4. Steffel, J. & Luscher, T. F. Vitamin K antagonists: Ready to be replaced? Hamostaseologie 32, 249-257 (2012).
5. Giorgi, M. A., Cohen Arazi, H., Gonzalez, C. D. & Di Girolamo, G. Changing anticoagulant paradigms for atrial fibrillation: Dabigatran, apixaban and rivaroxaban. Expert Opin. Pharmacother. 12, 567-577 (2011).
6. Harder, S., Parisius, J. & Picard-Willems, B. Monitoring direct FXa-inhibitors and fondaparinux by prothrombinase-induced clotting time (PiCT): Relation to FXa-activity and influence of assay modifications. Thromb. Res. 123, 396-403 (2008).
7. Brenner, B. & Hoffman, R. Emerging options in the treatment of deep vein thrombosis and pulmonary embolism. Blood Rev. 25, 215-221 (2011).
8. Blech, S., Ebner, T., Ludwig-Schwellinger, E., Stangier, J. & Roth, W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab. Dispos. 36, 386-399 (2008).
9. Stangier, J., Rathgen, K., Stahle, H. & Mazur, D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: An open-label, parallel-group, single-centre study. Clin. Pharmacokinet. 49, 259-268 (2010).
10. Stangier, J., Rathgen, K., Stahle, H., Gansser, D. & Roth, W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br. J. Clin. Pharmacol. 64, 292-303 (2007).
11. van Ryn, J. et al. Dabigatran etexilate-A novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb. Haemost. 103, 1116-1127 (2010).
12. Schulman, S. et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II) [abstract 205]. Presented at the American Society of Hematology 2011 Annual Meeting.
13. Eriksson, B. I. et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: The REMODEL randomized trial. J. Thromb. Haemost. 5, 2178-2185 (2007).
14. RE-MOBILIZE Writing Committee et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J. Arthroplasty 24, 1-9 (2009).
15. Eriksson, B. I. et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, non-inferiority trial. Lancet 370, 949-956 (2007).
16. Eriksson, B. I. et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II): A randomised, double-blind, non-inferiority trial. Thromb. Haemost. 105, 721-729 (2011).
17. Schulman, S. et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med. 361, 2342-2352 (2009).
18. Prandoni, P. & Taher, A. Insights from the dabigatran versus warfarin trial in patients with venous thromboembolism (the RECOVER trial). Expert Opin. Pharmacother. 11, 1035-1037 (2010).
19. Schulman, S. et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N. Engl. J. Med. 368, 709-718 (2013).
20. Dans, A. L. et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation 127, 634-640 (2013).
21. Uchino, K. & Hernandez, A. V. Dabigatran association with higher risk of acute coronary events: Meta-analysis of noninferiority randomized controlled trials. Arch. Intern. Med. 172, 397-402 (2012).
22. Perzborn, E. et al. Rivaroxaban: A new oral factor Xa inhibitor. Arterioscler. Thromb. Vasc. Biol. 30, 376-381 (2010).
23. Baumann Kreuziger, L. M., Morton, C. T. & Dries, D. J. New anticoagulants: A concise review. J. Trauma Acute Care Surg. 73, 983-992 (2012).
24. Eriksson, B. I. et al. Rivaraoxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med. 388, 2765-2775 (2008).
25. Kakkar, A. K. et al. Extended duration rivaroxaban versus short term enoxaparin for the prevention of VTE after total hip arthroplasty. Lancet 372, 31-39 (2008).
26. Lassen, M. R. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N. Engl. J. Med. 358, 2776-2786 (2008).
27. Turpie, A. G. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): A randomized trial. Lancet 373, 1673-1680 (2009).
28. Turun, S. et al. A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement. Thromb. Res. 127, 525-534 (2011).
29. Cohen, A. T. et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N. Engl. J. Med. 368, 513-523 (2013).
30. Raghavan, N. et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab. Dispos. 37, 74-81 (2009).
31. EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N. Engl. J. Med. 363, 2499-2510 (2010).
32. EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N. Engl. J. Med. 366, 1287-1297 (2012).
33. Prandoni, P. Anticoagulant treatment of pulmonary embolism: Impact and implications of the EINSTEIN PE study. Eur. J. Haematol. 89, 281-287 (2012).
34. Romualdi, E., Donadini, M. P. & Ageno, W. Oral rivaroxaban after symptomatic venous thromboembolism: The continued treatment study (EINSTEIN-extension study). Expert Rev. Cardiovasc. Ther. 9, 841-844 (2011).
35. Lassen, M. R. et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N. Engl. J. Med. 361, 594-604 (2009).
36. Lassen, M. R. et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE2): A randomised double-blind trial. Lancet 375, 807-815 (2010).
37. Lassen, M. R. et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N. Engl. J. Med. 363, 2487-2498 (2010).
38. Goldhaber, S. Z. et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N. Engl. J. Med. 365, 2167-2177 (2011).
39. US National Library of Medicine. ClinicalTrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00643201 (2012).
40. Agnelli, G. et al. Apixaban for extended treatment of venous thromboembolism. N. Engl. J. Med. 368, 699-708 (2013).
41. Ruff, C. T. et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AFTIMI 48). Am. Heart J. 160, 635-641 (2010).
42. Raskob, G. et al. Edoxaban for the long-term treatment of venous thromboembolism: Rationale and design of the Hokusai-VTE study. J. Thromb. Haemost. http://dx.doi.org/10.1111/jth.12230.
43. Yeh, C. H., Fredenburgh, J. C. & Weitz, J. I. Oral direct factor Xa inhibitors. Circ. Res. 111, 1069-1078 (2012).
44. Fuji, T., Fujita, S., Tachibana, S. & Kawai, Y. Edoxaban versus enoxaparin for the prevention of venous thromboembolism and bleeding from STARS E3 and STARS J.V [abstract 208]. Presented at the American Society of Hematology 2011 Annual Meeting.
45. Ahrens, I. & Bode, C. Oral anticoagulation with edoxaban. Focus on current phase III clinical development. Hamostaseologie 32, 212-215 (2012).
46. Raskob, G. et al. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement: A randomised double-blind dose-response study. Thromb. Haemost. 104, 642-649 (2010).
47. Fuji, T. et al. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J. Thromb. Haemost. 8, 2458-2468 (2010).
48. Piazza, G. et al. Venous thromboembolism in patients with symptomatic atherosclerosis. Thromb. Haemost. 106, 1095-1102 (2011).
49. Piazza, G. et al. Venous thromboembolism in patients with diabetes mellitus. Am. J. Med. 125, 709-716 (2011).
50. Prandoni, P. et al. An association between atherosclerosis and venous thrombosis. N. Engl. J. Med. 348, 1435-1441 (2003).
51. Prandoni, P. Venous thromboembolism and atherosclerosis: Is there a link? J. Thromb. Haemost. 5 (Suppl. 1), 270-275 (2007).
52. Prandoni, P. Links between arterial and venous disease. J. Intern. Med. 262, 341-350 (2007).
53. O'Gara, P. T. et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation 127, e362-e425 (2013).
54. Fiessinger, J. N. et al. Ximelagatran vs lowmolecular-weight heparin and warfarin for the treatment of deep vein thrombosis: A randomized trial. JAMA 293, 681-689 (2005).
55. Olsson, S. B. et al. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with nonvalvular atrial fibrillation (SPORTIF III): Randomised controlled trial. Lancet 362, 1691-1968 (2003).
56. Albers, G. W. et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: A randomized trial. JAMA 293, 690-698 (2005).
57. Artang, R., Rome, E. & Vidaillet, H. Dabigatran and myocardial infarction, drug or class effect: Meta-analysis of randomized trials with oral direct thrombin inhibitors [abstract]. J. Am. Coll. Cardiol. 59, E571 (2012).
58. Komocsi, A., Vorobcsuk, A., Kehl, D. & Aradi, D. Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: Systematic review and meta-analysis of randomized controlled trials. Arch. Intern. Med. 172, 1537-1545 (2012).
59. Thomas, K. A promising drug with a flaw. The New York Times (2 November 2012).
60. Eerenberg, E. S. et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124, 1573-1579 (2011).
61. Crowther, M. A. & Warkentin, T. E. Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents. J. Thromb. Haemost. 7 (Suppl. 1), 107-110 (2009).
62. Marlu, R. et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: A randomised crossover ex vivo study in healthy volunteers. Thromb. Haemost. 108, 217-224 (2012).
63. van Ryn, J. et al. Dabigatran etexilate-A novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb. Haemost. 103, 1116-1127 (2010).
64. Akwaa, F. & Spyropoulos, A. C. Treatment of bleeding complications when using oral anticoagulants for prevention of strokes. Curr. Treat. Options Cardiovasc. Med. http://dx.doi.org/10.1007/s11936-013-0238-5.
65. Godier, A. et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 116, 94-102 (2012).
66. Hollenbach, S. J. et al. PRT064445 but not recombinant FVIIa reverses rivaroxaban induced anticoagulation as measured by reduction in blood loss in a rabbit liver laceration model [abstract 3414]. Presented at the American Society of Hematology 2012 Annual Meeting.
67. Kaatz, S. et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am. J. Hematol. 87 (Suppl. 1), S141-S145 (2012).
68. Samama, M. M. et al. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb. Haemost. 103, 815-825 (2010).
69. Poulsen, B. K., Grove, E. L. & Husted, S. E. New oral anticoagulants: A review of the literature with particular emphasis on patients with impaired renal function. Drugs 72, 1739-1753 (2012).
70. Baber, U., van der Zee, S. & Fuster, V. Anticoagulation for mechanical heart valves in patients with and without atrial fibrillation. Curr. Cardiol. Rep. 12, 133-139 (2010).
71. Price, J., Hynes, M., Labinaz, M., Ruel, M. & Boodhwani, M. Mechanical valve thrombosis with dabigatran. J. Am. Coll. Cardiol. 60, 1710-1711 (2012).
72. Van de Werf, F. et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: The randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (REALIGN). Am. Heart J. 163, 931-937, e1 (2012).
73. Heit, J. A. et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: A 30-year population-based study. Ann. Intern. Med. 143, 697-706 (2005).
74. James, A. H., Jamison, M. G., Brancazio, L. R. & Myers, E. R. Venous thromboembolism during pregnancy and the postpartum period: Incidence, risk factors, and mortality. Am. J. Obstet. Gynecol. 194, 1311-1315 (2006).
75. Forestier, F., Daffos, F. & Capella-Pavlovsky, M. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy study by direct fetal blood sampling under ultrasound. Thromb. Res. 34, 557-560 (1984).
76. Ginsberg, J. S., Hirsh, J., Turner, D. C., Levine, M. N. & Burrows, R. Risks to the fetus of anticoagulant therapy during pregnancy. Thromb. Haemost. 61, 197-203 (1989).
77. Romualdi, E. et al. Anticoagulant therapy for venous thromboembolism during pregnancy: A systematic review and a meta-analysis of the literature. J. Thromb. Haemost. 11, 270-281 (2013).
78. Jacobsen, A. F. & Sandset, P. M. Venous thromboembolism associated with pregnancy and hormonal therapy. Best Pract. Res. Clin. Haematol. 25, 319-332 (2012).
79. Stone, S. E. & Morris, T. A. Pulmonary embolism during and after pregnancy. Crit. Care Med. 33 (Suppl. 10), S294-S300 (2005).
80. Sorensen, H. T., Mellemkjaer, L., Olsen, J. H. & Baron, J. A. Prognosis of cancers associated with venous thromboembolism. N. Engl. J. Med. 343, 1846-1850 (2000).
81. Chew, H. K., Wun, T., Harvey, D., Zhou, H. & White, R. H. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch. Intern. Med. 166, 458-464 (2006).
82. Kuderer, N. M., Ortel, T. L. & Francis, C. W. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J. Clin. Oncol. 27, 4902-11 (2009).
83. Horsted, F., West, J. & Grainge, M. J. Risk of venous thromboembolism in patients with cancer: A systematic review and meta-analysis. PLoS Med. 9, e1001275 (2012).
84. Young, A. et al. Thrombosis and cancer. Nat. Rev. Clin. Oncol. 9, 437-449 (2012).
85. Lyman, G. H. et al. American Society of Clinical Oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J. Clin. Oncol. 25, 5490-5505 (2007).
86. Lee, A. Y. et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med. 349, 146-153 (2003).
87. Verso, M. & Agnelli, G. New and old anticoagulants in cancer. Thromb. Res. 129 (Suppl. 1), S101-S105 (2012).
88. Farge, D. et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J. Thromb. Haemost. 11, 56-70 (2013).
89. Levine, M. N. New antithrombotic drugs: Potential for use in oncology. J. Clin. Oncol. 27, 4912-4918 (2009).
90. Turpie, A. G. et al. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb. Haemost. 101, 68-76 (2009).